{"id":38631,"date":"2026-02-18T04:30:03","date_gmt":"2026-02-18T04:30:03","guid":{"rendered":"https:\/\/g-medtech.com\/news\/?p=38631"},"modified":"2026-02-18T04:30:59","modified_gmt":"2026-02-18T04:30:59","slug":"levee-medical-secures-over-12m-to-advance-pma-plans-for-voro-urologic-scaffold","status":"publish","type":"post","link":"https:\/\/g-medtech.com\/news\/levee-medical-secures-over-12m-to-advance-pma-plans-for-voro-urologic-scaffold\/","title":{"rendered":"Levee Medical Secures Over $12M to Advance PMA Plans for Voro Urologic Scaffold"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/g-medtech.com\/database\/medtech-players\/index\/levee-medical\/\" target=\"_blank\" rel=\"noreferrer noopener\">Levee Medical<\/a> has raised more than $12 million in an oversubscribed financing round to support its premarket approval process as the ARID II pivotal trial advances. The Durham, North Carolina\u2013based company said the funding was completed ahead of schedule and will extend its operating runway through key regulatory milestones.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The capital will primarily support activities related to the planned PMA submission following completion of enrollment in the ARID II study. The trial is evaluating the company\u2019s Voro Urologic Scaffold in men undergoing robotic-assisted radical prostatectomy. The multicenter, randomized study is designed to assess the device\u2019s safety and effectiveness in reducing complications associated with prostate cancer surgery.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cWe are grateful for the overwhelming investor support,\u201d said Adam Irving, CEO of Levee Medical. \u201cThe extended runway strengthens our position during the PMA process following ARID II enrollment. We are laser focused on meaningful results for patients and stakeholders.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Clinical participation in ARID II continues to expand. Ahmed Ghazi, MD, Professor of Urology at Johns Hopkins and Director of the Surgical Learning and Innovation Center of Excellence, said, \u201cYesterday we hosted ARID II principal investigator, Dr. Scott Eggener, Chair of Urology at UCLA, who is our 40th surgeon to participate. Our goal is to mobilize leadership among clinical research sites, standardizing an evidence-based, effective and reproducible implant technique for the scaffold during the IDE trial.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scott Cheney, MD, who is leading the study at <a href=\"https:\/\/g-medtech.com\/directory\/listings\/mayo-clinic\/\" target=\"_blank\" rel=\"noreferrer noopener\">Mayo Clinic<\/a>, emphasized the clinical focus of the research. \u201cStress urinary incontinence is one of the most feared outcomes after radical prostatectomy,\u201d he said. \u201cI&#8217;m excited to help lead the ARID II study at Mayo Clinic, focused on minimizing early incontinence and accelerating recovery for our patients.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Levee Medical has closed an oversubscribed financing round exceeding $12 million to support its PMA process as enrollment progresses in the ARID II pivotal trial of its Voro Urologic Scaffold.<\/p>\n","protected":false},"author":2,"featured_media":38630,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"colormag_page_layout":"default_layout","footnotes":""},"categories":[7,488,681,10],"tags":[594],"class_list":["post-38631","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-americas","category-breaking-news","category-care-therapy","category-strategic-development","tag-financing"],"_links":{"self":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/38631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/comments?post=38631"}],"version-history":[{"count":2,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/38631\/revisions"}],"predecessor-version":[{"id":38633,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/38631\/revisions\/38633"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/media\/38630"}],"wp:attachment":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/media?parent=38631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/categories?post=38631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/tags?post=38631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}